Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.6928
-$0.0272-3.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.18M | 7.89M | 7.80M | 8.19M | 8.72M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.41M | 30.80M | 34.13M | 37.24M | 40.44M |
| Operating Income | -29.41M | -30.80M | -34.13M | -37.24M | -40.44M |
| Income Before Tax | -28.90M | -29.90M | -33.00M | -35.97M | -39.82M |
| Income Tax Expenses | 17.30K | 19.50K | 10.20K | 22.30K | 21.30K |
| Earnings from Continuing Operations | -28.92 | -29.92 | -33.01 | -35.99 | -39.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.92M | -29.92M | -33.01M | -35.99M | -39.84M |
| EBIT | -29.41M | -30.80M | -34.13M | -37.24M | -40.44M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.80 | -0.92 | -1.10 | -1.33 | -1.59 |
| Normalized Basic EPS | -0.50 | -0.57 | -0.69 | -0.83 | -1.00 |
| EPS Diluted | -0.80 | -0.92 | -1.10 | -1.33 | -1.59 |
| Normalized Diluted EPS | -0.50 | -0.57 | -0.69 | -0.83 | -1.00 |
| Average Basic Shares Outstanding | 151.32M | 132.56M | 121.47M | 111.31M | 103.19M |
| Average Diluted Shares Outstanding | 151.32M | 132.56M | 121.47M | 111.31M | 103.19M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |